Molecular Templates, Inc.
DelistedCIK 1183765fmd_0P5QKJJXNF48FQHV7WX09HMSJHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2001 to Jun 30, 2024, 66 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 2 | 3 | 13 | 22 | – | – | – | – |
| Research and development | 36 | 40 | 8 | 9 | 30 | 51 | 93 | 85 | 82 | 49 |
| Total operating expenses | 46 | 50 | 12 | 21 | 44 | 93 | 120 | 119 | 109 | 68 |
| Operating income | (31) | 27 | (11) | (18) | (31) | (70) | (101) | (80) | (89) | (10) |
| Interest expense | – | – | 0 | 1 | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | 1 | 1 |
| Other non-operating income (expense) | 9 | 17 | 0 | – | – | – | – | – | – | – |
| Income before taxes | (22) | 44 | (24) | – | – | (69) | (105) | (83) | (93) | (8) |
| Income tax expense | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0) |
| Net income from continuing operations | (22) | 44 | (24) | – | – | (69) | (105) | (83) | (93) | (8) |
| Net income | (22) | 44 | (11) | (23) | (30) | (69) | (105) | (83) | (93) | (8) |
| Net income to common shareholders | (31) | 40 | (13) | (24) | (30) | (69) | (105) | (83) | (93) | (8) |